Current status and future perspectives of leukocytapheresis for inflammatory bowel disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 6, 2012, Pages 997-1003

  Fukunaga, Ken ^a   Matsumoto, Takayuki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Crohn's disease; Granulocyte monocyte apheresis; Inflammatory bowel disease; Leukocytapheresis; Ulcerative colitis

Indexed keywords

ADSORPTIVE GRANULOCYTE MONOCYTE APHERESIS; ARTICLE; CROHN DISEASE; ENTERITIS; FILTRATION LEUKOCYTAPHERESIS; HUMAN; JAPAN; LEUKAPHERESIS; LEUKOCYTAPHERESIS; PRIORITY JOURNAL; RELAPSE; TREATMENT PLANNING; ULCERATIVE COLITIS;

EID: 84861468551     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07119.x     Document Type: Article

References (56)

1. Isaacs KL, Lewis JD, Sandborn WJ, Sands BE, Targan SR. State of the art: IBD therapy and clinical trials in IBD. Inflamm. Bowel Dis. 2005; 11: S3-S12.
2. Allison MC, Dhillon AP, Lewis WG, eds. Inflammatory Bowel Disease. London: Mosby, 1998; 9-95.
3. Sawada K, Muto T, Shimoyama T etal. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr. Pharm. Des. 2003; 9: 307-21.
4. Shimoyama T, Sawada K, Hiwatashi N etal. Safety and efficacy of granulocytes and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J. Clin. Apher. 2001; 16: 1-9.
5. Fukuda Y, Matsui T, Suzuki Y etal. Adsorptive granulocyte and monocyte apheresis for refractory Crohn's disease: an open multicenter prospective study. J. Gastroenterol. 2004; 39: 1158-64.
6. Sawada K, Ohnishi K, Fukui S etal. Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease. J. Gastroenterol. 1995; 30: 322-9.
7. Shibata H, Kuriyama T, Yamawaki N. Cellsorba. Ther. Apher. Dial. 2003; 7: 44-7.
8. Saniabadi AR, Hanai H, Suzuki Y etal. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J. Clin. Apher. 2005; 20: 171-84.
9. Hiraishi K, Takeda Y, Shiobara N etal. Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis. Ther. Apher. Dial. 2003; 7: 334-40.
10. D'Arrigo C, Candal-Couto JJ, Greer M etal. Human neutrophil Fc receptor-mediated adhesion under flow: a hallow fiber model of intravascular arrest. Clin. Exp. Immunol. 1993; 100: 173-9.
11. Sakuraba A, Motoya S, Watanabe K etal. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am. J. Gastroenterol. 2009; 104: 2990-5.
12. Sands BE, Sandborn WJ, Feagan B etal. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 2008; 135: 400-9.
13. Kosaka T, Sawada K, Ohnishi K etal. Effect of leukocytapheresis therapy using a leukocyte removal filter in Crohn's disease. Intern. Med. 1999; 38: 102-11.
14. Matsui T, Nishimura T, Matake H, Ohta T, Sakurai T, Yao T. Granulocytapheresis for Crohn's disease: a report on seven refractory patients. Am. J. Gastroenterol. 2003; 98: 511-12.
15. Kusaka T, Fukunaga K, Ohnishi K etal. Adsorptive monocyte-granulocytapheresis (M-GCAP) for refractory Crohn's disease. J. Clin. Apher. 2004; 19: 168-73.
16. Matsumoto T, Andoh A, Okawa K etal. Multivariate analysis for factors predicting rapid response of leukocytapheresis in patients with steroid-resistant ulcerative colitis: a multicenter prospective open-label study. Ther. Apher. Dial. 2008; 12: 484-90.
17. Noguchi M, Hiwatashi N, Hayakawa T, Toyota T. Leukocyte removal filter-passed lymphocytes produce large amounts of interleukin-4 in immunotherapy for inflammatory bowel disease: role of bystander suppression. Ther. Apher. 1998; 2: 109-14.
18. Hanai H, Iida T, Takeuchi K etal. Decrease of reactive-oxygen -producing garnulocytes and release of IL-10 into the peripheral blood following leukocytapheresis in patients with active ulcerative colitis. World J. Gastroenterol. 2005; 11: 3085-90.
19. Sakaguchi S, Sakaguchi N, Shimizu J etal. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 2001; 182: 18-32.
20. Kosaka T, Sawada K, Ohnishi K etal. Effect of leukocytapheresis therapy using a leukocyte removal filter in Crohn's disease. Expert Opin. Biol. Ther. 2005; 5: 451-62.
21. Andoh A, Tsujikawa T, Inatomi O etal. Leukocytapheresis therapy modulates circulating t cell subsets in patients with ulcerative colitis. Ther. Apher. Dial. 2005; 9: 270-6.
22. Kanai T, Makita S, Kawamura T etal. Extracorporeal elimination of TNF-alpha-producing CD14(dull)CD16(+) monocytes in leukocytapheresis therapy for ulcerative colitis. Inflamm. Bowel Dis. 2007; 13: 284-90.
23. Hanai H, Iida T, Takeuchi K etal. Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease. Am. J. Gastroenterol. 2008; 103: 1210-16.
24. Danese S, Motte C, Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am. J. Gastroenterol. 2004; 99: 938-45.
25. Talstad I, Rootwelt K, Gjone E. Thrombocytosis in ulcerative colitis and Crohn's disease. Scand. J. Gastroenterol. 1973; 8: 135-8.
26. Harries AD, Fitzsimons E, Fifield R, Dew MJ, Rhoades J. Platelet count: a simple measure of activity in Crohn's disease. Br. Med. J. 1983; 286: 1476.
27. Fukunaga K, Fukuda Y, Yokoyama Y etal. Activated platelet as a possible early marker to predict clinical efficacy of Leukocytapheresis in severe ulcerative colitis patients. J. Gastroenterol. 2006; 41: 524-32.
28. Kanke K, Nakano M, Hiraishi H etal. Evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig. Liver Dis. 2004; 36: 512-18.
29. Naganuma M, Funakoshi S, Sakuraba A etal. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm. Bowel Dis. 2004; 10: 251-7.
30. Yamamoto T, Umegae S, Kitagawa T etal. Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study. Aliment. Pharmacol. Ther. 2004; 20: 783-92.
31. Domenech E, Hinojosa J, Esteve-Comas M etal. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment. Pharmacol. Ther. 2004; 20: 1347-52.
32. Passalacqua S, Ferraro PM, Bresci G etal. The Italian registry of therapeutic apheresis: granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric study. J. Clin. Apher. 2011; 26: 332-7.
33. Sakata Y, Iwakiri R, Amemori S etal. Comparison of the efficacy of granulocyte and monocyte/macrophage adsorptive apheresis and leukocytapheresis in active ulcerative colitis patients: a prospective randomized study. Eur. J. Gastroenterol. Hepatol. 2008; 20: 629-33.
34. Saniabadi AR, Hanai H, Lofberg R etal. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther. Apher. Dial. 2003; 7: 48-59.
35. Hanai H, Watanabe F, Takeuchi K etal. Leukcocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective uncontrolled pilot study. Clin. Gastroenterol. Hepatol. 2003; 1: 28-35.
36. McCarthy DA, Rampton DS, Liu Y-C. Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin. Exp. Immunol. 1991; 86: 489-93.
37. Rugtveit J, Brandtzaeg P, Halstensen TS etal. Increased macrophage subsets in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut 1994; 35: 669-74.
38. Meuret G, Bitzi A, Hammer B. Macrophage turnover in Crohn's disease and ulcerative colitis. Gastroenterology 1978; 74: 501-3.
39. Brannigan AE, O'Connell PR, Hurley H. Neutrophil apoptosis is delayed in patients with inflammatory bowel disease. Shock 2000; 13: 361-6.
40. Cassatella MA. The production of cytokines by polymorphonuclear neutrophils. Immunol. Today 1995; 16: 21-6.
41. Nikolaus S, Bauditz J, Gionchetti P. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin-10 during intestinal inflammation. Gut 1998; 42: 470-6.
42. Tibble JA, Sigthorsson G, Bridger D etal. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 15-22.
43. Limburg P, David M, Ahlquist A, Sandborn WJ. Faecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhoea referred for colonoscopy. Am. J. Gastroenterol. 2000; 95: 2831-7.
44. + T-cell subsets in patients with ulcerative colitis: modified by selective leucocytapheresis. Dig. Dis. Sci. 2007; 52: 2725-31.
45. Kamikozuru K, Fukunaga K, Hirota S etal. The expression profile of functional regulatory T cells, CD4+CD25high+/forkhead box protein P3+, in patients with ulcerative colitis during active and quiescent disease. Clin. Exp. Immunol. 2009; 156: 320-7.
46. Kashiwagi N, Sugimura K, Koiwai H, Saniabadi A. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig. Dis. Sci. 2002; 6: 1334-41.
47. Andoh A, Tsujikawa T, Inatomi O etal. Suppression of inflammatory cytokines secretion by granulocyte/monocytes adsorptive apheresis in active ulcerative colitis. Ther. Apher. Dial. 2005; 2: 123-7.
48. Yoshino T, Nakase H, Matsuura M etal. Effect and safety of granulocyte-monocyte adsorption apheresis for patients with ulcerative colitis positive for cytomegalovirus in comparison with immunosuppressants. Digestion 2011; 84: 3-9.
49. Fukunaga K, Kamikozuru K, Yokoyama Y etal. Optimal apheresis treatment volume for the efficacy and safety of leukocytapheresis with Cellsorba in patients with active ulcerative colitis. J. Clin. Apher. 2011; 26: 326-31.
50. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey; Final Report of Findings. Cited 22 Mar 2011. Available from URL:
51. Ministry of Health, Labor and Welfare. Annual Report of the Survey for Health and Nutrition in the Citizen 2009. [Japanese]. Cited 22 Mar 2011. Available from URL:
52. Kikuyama R, Fukunaga K, Kawai M etal. Relevance of the processed blood volume per granulocyte and monocyte apheresis session to its clinical efficacy in patients with ulcerative colitis. Ther. Apher. Dial. 2011; 15: 360-6.
53. Yoshimura N, Tadami T, Kawaguchi T etal. Processed blood volume impacts clinical efficacy in patients with ulcerative colitis undergoing adsorptive depletion of myeloid lineage leucocytes. J. Gastroenterol. 2011; 47: 49-55.
54. Gornet JM, Couve S, Hassani Z etal. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Aliment. Pharmacol. Ther. 2003; 18: 175-81.
55. Fukunaga K, Yokoyama Y, Kamikozuru K etal. A prospective randomized double blind sham controlled trial to assess the efficacy of monthly Granulocyte/ Monocyte adsorption Apheresis as maintenance therapy for patients with steroid refractory ulcerative colitis. Gut 2010; 59 (Suppl. III): A73.
56. Fukunaga K, Yokoyama Y, Kamikozuru K etal. Selective depletion of peripheral granulocyte/monocyte enhances the efficacy of scheduled maintenance infliximab in Crohn's disease. J. Clin. Apher. 2010; 25: 226-8.